This is an observational study designed to evaluate the safety and clinical outcomes of the MANTA® Vascular Closure Device (VCD) (the MANTA® Device) in TAVR procedures. The study will enroll participants who are undergoing a TAVR procedure. The purpose of this study is to examine and collect data on outcomes of contemporary MANTA® large bore closure in standard of care (SOC) TAVR procedures with on-label use of the MANTA® device including appropriate patient selection and proper vascular access.
In the U.S. and Canada, the MANTA® Vascular Closure Device is indicated for closure of femoral arterial access sites while reducing time to hemostasis following the use of 10-20F devices or sheaths (12-25F OD) in endovascular catheterization procedures. In Israel, the 14F MANTA® is indicated for closure of femoral arterial access sites following the use of 10-14F devices or sheaths (maximum OD/profile of 18F), and the 18F MANTA® device is indicated for closure of femoral arterial access sites following the use of 15-18F devices or sheaths (maximum OD/profile of 25F). The purpose of the study is to examine and collect data on outcomes of contemporary MANTA® large bore closure in standard of care (SOC) TAVR procedures with on-label use of the MANTA® device including appropriate patient selection and proper vascular access.
Study Type
OBSERVATIONAL
Enrollment
258
The MANTA® Vascular Closure Device consists of a 14F or 18F MANTA® Closure Device, a 14F or 18F Sheath with Introducer, and an 8F Depth Locator. In the U.S. and Canada, the MANTA® Vascular Closure Device is indicated for closure of femoral arterial access sites while reducing time to hemostasis following the use of 10-20F devices or sheaths (12-25F OD) in endovascular catheterization procedures.
Baptist Health Medical Center-Jacksonville
Jacksonville, Florida, United States
Orlando Health, Inc
Orlando, Florida, United States
Henry Ford Health
Detroit, Michigan, United States
Rate of VARC-3 Major & Minor Vascular complications
Time frame: within 30 days of TAVR procedure
Time to Hemostasis
The elapsed time between MANTA® deployment and first observed and confirmed arterial hemostasis
Time frame: During the procedure
Additional interventions: Required at large bore access site to address complications
The percentage of subjects with additional interventions required at large bore access site to address bleeding or other large bore access site complications (e.g., bare or covered stent or surgical repair), within 30 days following the procedure
Time frame: within 30 days following the procedure
Technical Success:
The percentage of subjects in whom closure is obtained with the MANTA® VCD without the use of unplanned endovascular or surgical intervention
Time frame: During the procedure
Ambulation Success:
The percentage of a previously ambulatory subjects (until day of TAVI) who are able to ambulate for at least 20 feet/6 meters without re-bleeding.
Time frame: During procedure admission
Treatment Success:
The percentage of subjects in whom the time to Hemostasis ≤10 minutes and have no Large Bore Access Related Major VARC-3 complications within 30 days.
Time frame: within 30 days of TAVR procedure
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
University at Buffalo
Buffalo, New York, United States
North Shore University Hospital
Manhasset, New York, United States
Mount Sinai Hospital
New York, New York, United States
Montefiore Medical Center
New York, New York, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Baylor Scott & White - Round Rock
Round Rock, Texas, United States
Montreal Heart Institute
Montreal, Quebec, Canada